Eli Lilly 관리

관리 기준 확인 2/4

Eli Lilly CEO는 Dave Ricks, Jan2017 에 임명되었습니다 의 임기는 7.83 년입니다. 총 연간 보상은 $ 26.57M, 6.1% 로 구성됩니다. 6.1% 급여 및 93.9% 보너스(회사 주식 및 옵션 포함). 는 $ 475.81M 가치에 해당하는 회사 주식의 0.067% 직접 소유합니다. 475.81M. 경영진과 이사회의 평균 재임 기간은 각각 6.2 년과 8.4 년입니다.

주요 정보

Dave Ricks

최고 경영자

US$26.6m

총 보상

CEO 급여 비율	6.1%
CEO 임기	7.8yrs
CEO 소유권	0.07%
경영진 평균 재임 기간	6.2yrs
이사회 평균 재임 기간	8.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Dave Ricks 의 보수는 Eli Lilly 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	US$8b
Jun 30 2024	n/a	n/a	US$7b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$27m	US$2m	US$5b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$21m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$6b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$24m	US$1m	US$6b
Sep 30 2020	n/a	n/a	US$6b
Jun 30 2020	n/a	n/a	US$6b
Mar 31 2020	n/a	n/a	US$6b
Dec 31 2019	US$21m	US$1m	US$5b
Sep 30 2019	n/a	n/a	US$4b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$17m	US$1m	US$3b
Sep 30 2018	n/a	n/a	US$372m
Jun 30 2018	n/a	n/a	-US$166m
Mar 31 2018	n/a	n/a	US$1b
Dec 31 2017	US$16m	US$1m	-US$86m

보상 대 시장: Dave 의 총 보상 ($USD 26.57M )은 CL 시장( $USD 5.72M ).

보상과 수익: Dave 의 보상은 지난 1년 동안 20% 이상 증가했습니다.

CEO

Dave Ricks (56 yo)

7.8yrs

테뉴어

US$26,565,732

보상

Mr. David A. Ricks, also known as Dave, has been a Director of Adobe Inc. since April 12, 2018 and previously served as its Director since June 2017. He served as a Director of Elanco Animal Health Incorpo...

리더십 팀

이름	위치	테뉴어	보상	소유권
David Ricks	Chairman	7.8yrs	US$26.57m	0.067% $ 475.8m
Daniel Skovronsky	EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology	6.4yrs	US$11.85m	0.021% $ 152.1m
Anat Hakim	Executive VP	4.8yrs	US$7.01m	0.0034% $ 23.9m
Jacob Van Naarden	Executive VP & President of Loxo	no data	US$4.89m	0.0023% $ 16.1m
Lucas Montarce	Executive VP & CFO	less than a year	데이터 없음	0.0012% $ 8.7m
Donald Zakrowski	Senior VP of Finance & Chief Accounting Officer	12yrs	데이터 없음	0.00080% $ 5.7m
Diogo Rau	EVP & Chief Information and Digital Officer	3.5yrs	US$5.10m	0.0012% $ 8.7m
Alonzo Weems	EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer	3.4yrs	데이터 없음	0.00088% $ 6.2m
Eric Dozier	Executive Vice President of Human Resources & Diversity	1.9yrs	데이터 없음	0.00093% $ 6.6m
Jeffrey Simmons	Senior VP & President of Elanco Animal Health	16.8yrs	US$5.38m	데이터 없음
W. Moody	SVP of Global Active Pharmaceutical Ingredient	8.3yrs	데이터 없음	데이터 없음
Anne White	EVP & President of Lilly Neuroscience	6.2yrs	데이터 없음	0.0073% $ 51.5m

6.2yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: LLY 의 관리팀은 노련하고 경험 (평균 재직 기간 6.2 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
David Ricks	Chairman	7.8yrs	US$26.57m	0.067% $ 475.8m
Gabrielle Greene-Sulzberger	Independent Director	3.8yrs	US$335.50k	데이터 없음
Sidney Taurel	Chairman Emeritus	15.8yrs	US$13.06m	데이터 없음
Jon Erik Fyrwald	Independent Director	19yrs	US$344.88k	0.000010% $ 70.8k
Ralph Alvarez	Independent Director	15.6yrs	US$336.00k	0.000080% $ 566.4k
William Kaelin	Independent Director	12.4yrs	US$349.15k	데이터 없음
Mary Hedley	Independent Director	2.5yrs	US$319.00k	0.000040% $ 283.2k
Juan Luciano	Lead Independent Director	8.8yrs	US$373.00k	데이터 없음
Katherine Baicker	Independent Director	12.9yrs	US$336.00k	데이터 없음
Jamere Jackson	Independent Director	8.1yrs	US$345.00k	데이터 없음
Karen Walker	Independent Director	5.9yrs	US$359.00k	데이터 없음
Kimberly Johnson	Independent Director	3.8yrs	US$316.00k	데이터 없음

8.4yrs

평균 재임 기간

62.5yo

평균 연령

경험이 풍부한 이사회: LLY 의 이사회는 경험(평균 재직 기간 8.4 년)으로 간주됩니다.

Eli Lilly 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Eli Lilly and Company Appoints Thomas J. Fuchs as First Chief AI Officer, Effective October 21, 2024

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Recent updates

Eli Lilly and Company Announces Detailed Results from the Phase 3 Survey-1 Three-Year Study

Eli Lilly and Company Announces Details of Presentations At the 2024 American Society of Hematology Annual Meeting

Third quarter dividend of US$1.30 announced

Eli Lilly and Company to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium

Third quarter 2024 earnings released: EPS: US$1.08 (vs US$0.064 loss in 3Q 2023)

Eli Lilly and Company Revises Earnings Guidance for the Year 2024

Lilly's Mirikizumab Is First and Only IL23p19 Antagonist to Report Long-Term, Multi-Year, Sustained Efficacy and Safety Data for Both Ulcerative Colitis and Crohn's Disease

Eli Lilly and Company Declares Fourth-Quarter 2024 Dividend, Payable on December 10, 2024

Lilly's EBGLYSS (Lebrikizumab-Lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab

Eli Lilly and Company to Report Q3, 2024 Results on Oct 30, 2024

Eli Lilly and Company Reports One-Year Histologic Outcomes in Phase 3 Study of Mirikizumab Compared to Ustekinumab for Crohn's Disease

Eli Lilly and Company Appoints Thomas J. Fuchs as First Chief AI Officer, Effective October 21, 2024

FDA Approves Lilly's EBGLYSS (Lebrikizumab-Lbkz) for Adults and Children 12 Years and Older with Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Positive Topline Results from the QWINT-1 and QWINT-3 Phase 3 Clinical Trials Evaluating Once Weekly Insulin Efsitora Alfa

Eli Lilly and Company Announces Positive Topline Results from the Surmount-1 Three-Year Study Evaluating the Efficacy and Safety of Tirzepatide

Eli Lilly and Company Announces Positive Topline Results from the Surmount-1 Three-Year Study Evaluating the Efficacy and Safety of Tirzepatide

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

Second quarter 2024 earnings released: EPS: US$3.29 (vs US$1.96 in 2Q 2023)

Eli Lilly and Company Raises Earnings Guidance Full-Year 2024

Eli Lilly and Company to Report Q2, 2024 Results on Aug 08, 2024

Eli Lilly and Company to Report Q2, 2024 Results on Aug 08, 2024

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령